From: "McCallion, George (G)" <GMcCallion**At_Symbol_Here**DOW.COM>
Subject: Re: [DCHAS-L] Clarification on : working with a high potency compound
Date: Tue, 11 Feb 2014 16:28:52 +0000
Reply-To: DCHAS-L <DCHAS-L**At_Symbol_Here**MED.CORNELL.EDU>
Message-ID: 54EE680479B80F4AA0B0D04355A3D71D56854D**At_Symbol_Here**
In-Reply-To <8CDFD30A507F9B4DBFE1486FA3AFCF660A980C**At_Symbol_Here**MAILSRV.DELMAR.LOCAL>



The classification is correct for high potency. I would consider the level of PPE to be at an elevated status to include a double gloving procedure, as well as Tyvek (i.e., disposable) lab coats, sleeve covers and booties. If the API has a dust property, then the use of a PAPR is strongly suggested.


That being said, I would encourage you to draft an SOP on high hazard handling. You could do a search on the internet, but be very careful as not all classifications are the same.


Hope this helps.






George D. McCallion, Chemist

The Dow Chemical Company

Functional Coatings R&D

Mail Stop S23
400 Arcola Road

P.O. Box 7000

Collegeville, PA 19426

Phone: 610.244.6504

E-mail: GMcCallion**At_Symbol_Here**





From: DCHAS-L Discussion List [mailto:dchas-l**At_Symbol_Here**MED.CORNELL.EDU] On Behalf Of Nadejda Spassova
Sent: Tuesday, February 11, 2014 9:33 AM
Subject: [DCHAS-L] Clarification on : working with a high potency compound


Hi everybody,


Here is the clarification regarding my question : ‘’Working with a high potent compound’’


I am working in a pharmaceutical company and what I mean by high potency is very, very active compound (in that case active pharmaceutical ingredient = API) in the human body for the intended pharmacological effect. This generic drug that we will work on in the near future has a daily dosage of only 20 =B5g per day (for that reason I guess it was classified as high potent drug) compare to a low potent drug e.g. 20g per day.

On the other side the LD 50 (mouse) of this compound is 200mg per kg, so it is not very toxic.


Sorry about this misunderstanding and thanks to all of you for the efforts trying to answer my not clear enough question,







Nadejda Spassova, Ph.D

Research Scientist II, R&D                                                                 T 514.366.7950ext. 270


9321, Airlie Street, LaSalle, Quebec, Canada H8R 2B2              

The information transmitted in and attached to this email may contain legally privileged or confidential information that is intended solely for the recipient(s) or entity to which it is addressed. Delivery of this message to anyone other than the intended recipient(s) does not in any way waive this privilege or confidentiality. Any review, retransmission, or other use of this confidential information by persons or entities other than the intended recipient(s) is prohibited. If you have received this email in error, please contact the sender and delete this material from any computer.


L’information contenue dans cet email peut contenir de l’information l=E9galement privil=E9gi=E9e ou confidentielle qui s’adresse uniquement =E0(aux) destinataire(s) ou =E0 l’entit=E9. L’envoi de ce message =E0 quiconque autre que le(s) destinataire(s) n’=E9carte pas toutefois cette privil=E9gie ou cette confidentialit=E9. Toute r=E9vision, retransmission, ou autre utilisation de cette information confidentielle par des personnes ou des entit=E9s autre que le(s) destinataire(s) est interdit. Si vous avez re=E7u ce message par erreur, veuillez contacter l’exp=E9diteur et supprimer le message de votre ordinateur.

Previous post   |  Top of Page   |   Next post

The content of this page reflects the personal opinion(s) of the author(s) only, not the American Chemical Society, ILPI, Safety Emporium, or any other party. Use of any information on this page is at the reader's own risk. Unauthorized reproduction of these materials is prohibited. Send questions/comments about the archive to
The maintenance and hosting of the DCHAS-L archive is provided through the generous support of Safety Emporium.